Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Guided Therapeutics (GTHP) over the last 11 years, with Q3 2025 value amounting to $81.7 million.

  • Guided Therapeutics' Shares Outstanding (Diluted Average) rose 4321.6% to $81.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.7 million, marking a year-over-year increase of 4321.6%. This contributed to the annual value of $57.3 million for FY2024, which is 1214.14% up from last year.
  • Per Guided Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $81.7 million for Q3 2025, which was up 4321.6% from $78.8 million recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Shares Outstanding (Diluted Average) registered a high of $81.7 million during Q3 2025, and its lowest value of $49297.0 during Q1 2023.
  • In the last 5 years, Guided Therapeutics' Shares Outstanding (Diluted Average) had a median value of $51.0 million in 2023 and averaged $40.8 million.
  • As far as peak fluctuations go, Guided Therapeutics' Shares Outstanding (Diluted Average) tumbled by 9976.17% in 2023, and later skyrocketed by 11096152.5% in 2024.
  • Guided Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $13.4 million in 2021, then soared by 142.99% to $32.5 million in 2022, then soared by 57.3% to $51.1 million in 2023, then increased by 12.14% to $57.3 million in 2024, then skyrocketed by 42.47% to $81.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $81.7 million in Q3 2025, compared to $78.8 million in Q2 2025 and $68.3 million in Q1 2025.